Abstract:e20614 Background: Lung cancer remains the leading cause of cancer mortality worldwide. Early detection of lung cancer helps improve treatment and survival. Numerous aberrant DNA methylations have been reported in early-stage lung cancer. Here, we sought to identify novel DNA methylation biomarkers that could potentially be used for noninvasive early diagnosis of lung cancers. Methods: This prospective-specimen collection and retrospective-blinded-evaluation trial enrolled a total of 317 participants (198 tissues and 119 plasmas) comprising healthy controls, patients with lung cancer and benign disease from The First Affiliated Hospital of Soochow University between January 2020 and December 2021. Tissue and plasma samples were subjected to targeted bisulfite sequencing with a lung cancer specific panel targeting 9,307 differential methylation regions (DMRs). DMRs associated with lung cancer were identified by comparing the methylation profiles of tissue samples from patients with lung cancer and benign disease. Markers were selected with minimum redundancy and maximum relevance (mRMR) algorithm. A prediction model for lung cancer diagnosis was built through logistic regression algorithm and validated independently in tissue samples. Furthermore, the performance of this developed model was evaluated in a set of plasma cell-free DNA (cfDNA) samples. Results: We identified 7 DMRs corresponding to 7 differentially methylated genes (DMRs, including HOXB4, HOXA7, HOXD8, ITGA4, ZNF808, PTGER4, and B3GNTL1), highly associated with lung cancer by comparing the methylation profiles of lung cancer and benign nodule tissues. Based on the 7-DMR biomarker panel, we developed a new diagnostic model in tissue samples, termed “7-DMR model”, to distinguish lung cancers from benign diseases, achieving AUCs of 0.966 (95%CI: 0.933-1.000)/0.961 (0.924-1.000), sensitivities of 0.887 (0.824-0.951)/0.922 (0.863-0.980), specificities of 0.938 (0.889-0.986)/1.000 (1.000-1.000), and accuracies of 0.896 (0.835-0.957)/0.938 (0.886-0.991) in the discovery cohort (n = 96) and the independent validation cohort (n = 81), respectively. Furthermore, the 7-DMR model was applied to noninvasive discrimination of lung cancers and non-lung cancers including benign lung diseases and healthy controls in an independent validation cohort of plasma samples (n = 106), yielding an AUC of 0.935 (0.862-1.000), sensitivity of 0.808 (0.733-0.883), specificity of 0.975 (0.945-1.000), and accuracy of 0.934 (0.887-0.981). Conclusions: The 7 novel DMRs could be promising methylation biomarkers that merits further development as a noninvasive test for early detection of lung cancer.

Combination Analysis of PCDHGA12 and CDO1 DNA Methylation in Bronchial Washing Fluid for Lung Cancer Diagnosis

Identification and validation of PCDHGA12 and PRRX1 methylation for detecting lung cancer in bronchial washing sample

Quantitative analysis of a novel DNA hypermethylation panel using bronchial specimen for lung cancer diagnosis

Abstract 1029: Role of PCDHGA12 / PRRX1 methylation for the diagnosis of lung cancer using bronchial washing fluid

A comprehensive diagnostic scheme of morphological combined molecular methylation under bronchoscopy

Lung Tumor Discrimination by Deep Neural Network Model CanDo Via DNA Methylation in Bronchial Lavage

Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules

Diagnostic Accuracy Of Dna Methylation In Detection Of Gastric Cancer: A Meta-Analysis

Highly sensitive noninvasive early lung cancer detection using DNA methylation topology in sputum-derived epithelial cells

Diagnosis of pulmonary nodules by DNA methylation analysis in bronchoalveolar lavage fluids

Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation is a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions.

Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum

Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosome DNA Methylation Profile

Identification and Validation of the Methylation Biomarkers of Non-Small Cell Lung Cancer (NSCLC).

[Fluorescence in Situ Hybridization Combined with Cytomorphology for the Detection of Lung Cancer in Bronchial Brushing Specimens].

Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer

A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA

Detection of the DNA methylation of seven genes contribute to the early diagnosis of lung cancer

Early detection of lung cancer using a panel of circulating cell-free DNA methylation biomarkers.